Development · 10 Sep 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Indoco Remedies' Goa facility (Plant I) successfully passed a UKMHRA cGMP inspection with no critical or major observations.
Indoco Remedies' Goa plant (Plant I) manufacturing facility for solid dosages underwent a UKMHRA cGMP inspection from September 7 to September 9, 2026, concluding with no critical or major observations.
The UK-MHRA current Good Manufacturing Practices (cGMP) inspection of Indoco Remedies' solid dosages manufacturing facility in Goa concluded with no critical or major observations.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.